We considered the dipeptidyl peptidase-4 (DPP4) inhibitors a well-suited comparator for examining the effectiveness of another GLD because of their wide use in T2D treatment (American Diabetes Association, 2021) and the neutral effect on cardiovascular outcomes (Scirica et al., 2013; Green et al., 2015). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.